Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

2006 ◽  
Vol 47 (4) ◽  
pp. 629-636 ◽  
Author(s):  
Christos Emmanouilides ◽  
Thomas E. Witzig ◽  
Leo I. Gordon ◽  
Katie Vo ◽  
Gregory A. Wiseman ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ibritumomab Tiuxetan ◽  
Early Relapse ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Previously Treated ◽  
Yttrium 90

Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma

2007 ◽  
Vol 48 (9) ◽  
pp. 1736-1744 ◽  
Author(s):  
Jatin Shah ◽  
Wenquan Wang ◽  
V. Douglas Harrough ◽  
Wayne Saville ◽  
Ruby Meredith ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Yttrium 90

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma

2002 ◽  
Vol 29 (1) ◽  
pp. 87-92 ◽  
Author(s):  
Leo I Gordon ◽  
Thomas E Witzig ◽  
Greg A Wiseman ◽  
Ian W Flinn ◽  
Stewart S Spies ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Low Grade ◽  
Ibritumomab Tiuxetan ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Yttrium 90
Sign in / Sign up

Export Citation Format

Share Document